ONNVF.US Onco-Innovations Limited

Healthcare Biotechnology USA Stocks
0.1426 USD
Close of Nov 15, 2026
0.1387 1.19
Market cap
USD 9.87M
P/E
-
P/B
4.97x
ROE
-472.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.

Is ONNVF.US undervalued?

Graham number

The Graham number of Onco-Innovations Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Onco-Innovations Limited fundamental analysis

No fundamental analysis for Onco-Innovations Limited yet.

Onco-Innovations Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Onco-Innovations Limited

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada. The company's lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3'-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate precision oncology breakthroughs and de-risk drug development. …

Full company profile